shelf(0)

No. 002 · Repair · Recovery Peptide

TB-500

TB500Thymosin beta-4 fragmentAc-LKKTETQ

C Tier C · Animal data how tiers work →
  • Not FDA approved
  • WADA ✗ S2
Compare Cite
Fingerprint no sequence
TB-500 (no defined sequence)

No sequence on file. We only draw fingerprints from published sequences — this ring motif is a placeholder, never a guessed sequence.

01

Evidence

  1. D In vitro
  2. C Animal
  3. B Human pilot
  4. A RCT
  5. S Approved

TIER C — Evidence comes mostly from animal studies.

No human trials of TB-500 itself; supporting data come from animal studies and from research on full-length thymosin β4.

Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.

02

At a glance

Routes studied
Subcutaneous, Intramuscular Routes used in published research
FDA
Not approved
WADA
Prohibited · S2 Peptide hormones, growth factors, related substances and mimetics
03

Overview

A synthetic fragment of thymosin beta-4 that promotes tissue repair, cell migration, and blood vessel growth. Valued in recovery protocols for soft-tissue injuries.

Research status Preclinical research with strong anecdotal evidence; animal studies show robust tissue repair

04

Mechanism

TB-500 (thymosin beta-4 fragment) sequesters G-actin monomers and promotes actin polymerization, which drives cell migration and wound healing. It upregulates cell surface integrins and promotes angiogenesis, enabling new blood vessel formation at injury sites.

05

Effects reported in research

Reported outcomes, not promises. These come mostly from preclinical (cell or animal) research and have not been confirmed in human trials.

  • Enhanced wound healing and tissue repair
  • Reduced scar tissue formation
  • Improved flexibility and joint mobility
  • Promoted new blood vessel growth
06

Safety & unknowns

Limited human safety data. Animal studies show good tolerability. Potential concerns include theoretical tumor promotion due to angiogenic activity. Not FDA-approved. Banned by many sports organizations.

Unknowns. No randomized controlled trials in humans have been published, so human safety has not been established in controlled studies.

Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.

07

Studies [0]

No studies cited for this entry yet.

09

Status sources

Sources behind the tier, regulatory status, sequence and dates on this page.

10

Cite this entry

$ cite --format=apa

peptidemeta. (2026). TB-500. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/tb-500/

$ cite --format=bibtex 
@misc{peptidemeta-tb-500,
  title = {TB-500},
  author = {{peptidemeta}},
  year = {2026},
  howpublished = {\url{https://peptidemeta.com/p/tb-500/}},
  note = {Accessed 2026-11-08}
}

Accessed date reflects when you opened this page. Cite primary studies for scientific claims.

esc
↑↓ navigate ↵ open